Four Insiders Buying Diabetes Devices, But RSI Screams 75
The cluster here is real. Four insiders stepped in over the past 30 days, and CEO Devdatt Kurdikar just added $140,937 at $4.70. Problem is you're not getting anywhere near that price now. The stock ripped to $5.13 with RSI at 75 and money flow at 76, which means you'd be chasing a name stretched 12% above its own 8-day line. The bigger flag: every tracked insider buy on EMBC has lost money at 30 days, down about 13% on average. The people running the company clearly like these levels, but the tape and the history both say let this one cool off before you touch it.
The Filing
| Ticker | EMBC |
| Company | Embecta Corp. |
| Insider | Devdatt Kurdikar, President and CEO |
| Buy amount | $140,937 |
| Filing date | August 13, 2026 |
| Conviction | Interesting · 54/100 |
| Setup type | Overbought Entry |
Ultimate members received this analysis in real time.